-DOCSTART- -X- O
Recombinant -X- _ B-Intervention
vesicular -X- _ I-Intervention
stomatitis -X- _ I-Intervention
viruses -X- _ I-Intervention
( -X- _ I-Intervention
rVSVs -X- _ I-Intervention
) -X- _ I-Intervention
are -X- _ O
being -X- _ O
developed -X- _ O
as -X- _ O
potential -X- _ O
HIV-1 -X- _ B-Intervention
vaccine -X- _ I-Intervention
candidates. -X- _ O
To -X- _ O
characterize -X- _ O
the -X- _ O
in -X- _ O
vivo -X- _ O
replication -X- _ O
and -X- _ O
dissemination -X- _ O
of -X- _ O
rVSV -X- _ B-Intervention
vectors -X- _ I-Intervention
in -X- _ O
mice -X- _ B-Patient
, -X- _ O
high -X- _ O
doses -X- _ O
of -X- _ O
a -X- _ O
highly -X- _ B-Intervention
attenuated -X- _ I-Intervention
vector -X- _ I-Intervention
expressing -X- _ I-Intervention
HIV-1 -X- _ I-Intervention
Gag -X- _ I-Intervention
, -X- _ I-Intervention
rVSV -X- _ I-Intervention
( -X- _ I-Intervention
IN -X- _ I-Intervention
) -X- _ I-Intervention
- -X- _ I-Intervention
N4CT9-Gag1 -X- _ I-Intervention
, -X- _ I-Intervention
and -X- _ I-Intervention
a -X- _ I-Intervention
prototypic -X- _ I-Intervention
reference -X- _ I-Intervention
virus -X- _ I-Intervention
, -X- _ I-Intervention
rVSV -X- _ I-Intervention
( -X- _ I-Intervention
IN -X- _ I-Intervention
) -X- _ I-Intervention
-HIVGag5 -X- _ I-Intervention
, -X- _ I-Intervention
were -X- _ I-Intervention
delivered -X- _ I-Intervention
intramuscularly -X- _ I-Intervention
( -X- _ I-Intervention
IM -X- _ I-Intervention
) -X- _ I-Intervention
, -X- _ I-Intervention
intranasally -X- _ I-Intervention
( -X- _ I-Intervention
IN -X- _ I-Intervention
) -X- _ I-Intervention
, -X- _ I-Intervention
or -X- _ I-Intervention
intravenously -X- _ I-Intervention
( -X- _ I-Intervention
IV -X- _ I-Intervention
) -X- _ I-Intervention
. -X- _ O
We -X- _ O
used -X- _ O
quantitative -X- _ O
, -X- _ O
real-time -X- _ O
RT-PCR -X- _ O
( -X- _ O
Q-PCR -X- _ O
) -X- _ O
and -X- _ O
standard -X- _ O
plaque -X- _ O
assays -X- _ O
to -X- _ O
measure -X- _ O
the -X- _ O
temporal -X- _ O
dissemination -X- _ O
of -X- _ O
these -X- _ O
viruses -X- _ O
to -X- _ O
various -X- _ O
tissues. -X- _ O
Following -X- _ O
IM -X- _ O
inoculation -X- _ O
, -X- _ O
both -X- _ B-Outcome
viruses -X- _ I-Outcome
were -X- _ I-Outcome
detected -X- _ I-Outcome
primarily -X- _ I-Outcome
at -X- _ I-Outcome
the -X- _ I-Outcome
injection -X- _ I-Outcome
site -X- _ I-Outcome
as -X- _ I-Outcome
well -X- _ I-Outcome
as -X- _ I-Outcome
in -X- _ I-Outcome
draining -X- _ I-Outcome
lymph -X- _ I-Outcome
nodes -X- _ I-Outcome
; -X- _ O
neither -X- _ O
virus -X- _ O
induced -X- _ O
significant -X- _ O
weight -X- _ O
loss -X- _ O
, -X- _ O
pathologic -X- _ O
signs -X- _ O
, -X- _ O
or -X- _ O
evidence -X- _ O
of -X- _ O
neuroinvasion. -X- _ O
In -X- _ B-Outcome
contrast -X- _ I-Outcome
, -X- _ I-Outcome
following -X- _ I-Outcome
IN -X- _ I-Outcome
inoculation -X- _ I-Outcome
, -X- _ I-Outcome
the -X- _ I-Outcome
prototypic -X- _ I-Outcome
virus -X- _ I-Outcome
was -X- _ I-Outcome
detected -X- _ I-Outcome
in -X- _ I-Outcome
all -X- _ I-Outcome
tissues -X- _ I-Outcome
tested -X- _ I-Outcome
and -X- _ I-Outcome
caused -X- _ I-Outcome
significant -X- _ I-Outcome
weight -X- _ I-Outcome
loss -X- _ I-Outcome
leading -X- _ I-Outcome
to -X- _ I-Outcome
death. -X- _ I-Outcome
IN -X- _ B-Outcome
administration -X- _ I-Outcome
of -X- _ I-Outcome
rVSV -X- _ I-Outcome
( -X- _ I-Outcome
IN -X- _ I-Outcome
) -X- _ I-Outcome
-N4CT9-Gag1 -X- _ I-Outcome
resulted -X- _ I-Outcome
in -X- _ I-Outcome
detection -X- _ I-Outcome
in -X- _ I-Outcome
numerous -X- _ I-Outcome
tissues -X- _ I-Outcome
( -X- _ I-Outcome
brain -X- _ I-Outcome
, -X- _ I-Outcome
lung -X- _ I-Outcome
, -X- _ I-Outcome
nasal -X- _ I-Outcome
turbinates -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
lymph -X- _ I-Outcome
nodes -X- _ I-Outcome
) -X- _ I-Outcome
albeit -X- _ I-Outcome
in -X- _ I-Outcome
significantly -X- _ I-Outcome
reduced -X- _ I-Outcome
levels -X- _ I-Outcome
, -X- _ I-Outcome
which -X- _ I-Outcome
caused -X- _ I-Outcome
little -X- _ I-Outcome
or -X- _ I-Outcome
no -X- _ I-Outcome
weight -X- _ I-Outcome
loss -X- _ I-Outcome
nor -X- _ I-Outcome
any -X- _ I-Outcome
mortality. -X- _ I-Outcome
Following -X- _ O
IV -X- _ O
inoculation -X- _ O
, -X- _ O
both -X- _ O
prototypic -X- _ O
and -X- _ O
attenuated -X- _ O
viruses -X- _ O
were -X- _ O
detected -X- _ O
by -X- _ O
Q-PCR -X- _ O
in -X- _ O
all -X- _ O
tissues -X- _ O
tested. -X- _ O
In -X- _ O
contrast -X- _ O
to -X- _ O
the -X- _ O
prototype -X- _ O
, -X- _ O
rVSV -X- _ B-Outcome
( -X- _ I-Outcome
IN -X- _ I-Outcome
) -X- _ I-Outcome
-N4CT9-Gag1 -X- _ I-Outcome
viral -X- _ I-Outcome
loads -X- _ I-Outcome
were -X- _ I-Outcome
significantly -X- _ I-Outcome
lower -X- _ I-Outcome
in -X- _ I-Outcome
all -X- _ I-Outcome
organs -X- _ I-Outcome
tested -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
no -X- _ I-Outcome
infectious -X- _ I-Outcome
virus -X- _ I-Outcome
was -X- _ I-Outcome
detected -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
brain -X- _ I-Outcome
following -X- _ I-Outcome
IV -X- _ I-Outcome
inoculation -X- _ I-Outcome
, -X- _ I-Outcome
despite -X- _ I-Outcome
the -X- _ I-Outcome
presence -X- _ I-Outcome
of -X- _ I-Outcome
viral -X- _ I-Outcome
RNA. -X- _ I-Outcome
These -X- _ O
studies -X- _ O
demonstrated -X- _ O
significant -X- _ O
differences -X- _ O
in -X- _ O
the -X- _ O
biodistribution -X- _ O
patterns -X- _ O
of -X- _ O
and -X- _ O
the -X- _ O
associated -X- _ O
pathogenicity -X- _ O
engendered -X- _ O
by -X- _ O
the -X- _ O
prototypic -X- _ O
and -X- _ O
attenuated -X- _ O
vectors -X- _ O
in -X- _ O
a -X- _ O
highly -X- _ O
susceptible -X- _ O
host -X- _ O
. -X- _ O

